Inventor · disambiguated record
David Amantini
Also filed as: AMANTINI DAVID
15 granted patents·10 pending applications·56 citations·filing 2006–2022
90Inventor score
Top patents by PatentIndex Score
25 records- 0190US9926281B25-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritisGALAPAGOS NV·Filed 2015·Granted Mar 27, 2018·6 cites·18 claims
- 0288US10487060B25-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritisGALAPAGOS NV·Filed 2018·Granted Nov 26, 2019·4 cites·28 claims
- 0386US7803833B2CompoundsGLAXO GROUP LTD·Filed 2006·Granted Sep 28, 2010·10 cites·22 claims
- 0485US8129384B2Imidazo[1,2-a]pyrazines as orexin receptor antagonistsALVARO GIUSEPPE·Filed 2009·Granted Mar 6, 2012·7 cites·17 claims
- 0585US8093255B2Imidazo[1,2-A]pyrimidines as orexin receptor antagonistsALVARO GIUSEPPE·Filed 2009·Granted Jan 10, 2012·8 cites·17 claims
- 0684US8153623B2CompoundsALVARO GIUSEPPE·Filed 2010·Granted Apr 10, 2012·9 cites·18 claims
- 0782US11564923B2Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2018·Granted Jan 31, 2023·2 cites·19 claims
- 0882US8133908B2Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amineALVARO GIUSEPPE·Filed 2009·Granted Mar 13, 2012·10 cites·16 claims
- 0973US12472181B2Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2022·Granted Nov 18, 2025·0 cites·3 claims
- 1069US11718588B25-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritisGALAPAGOS NV·Filed 2021·Granted Aug 8, 2023·0 cites·16 claims
- 1168US10941117B25-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritisGALAPAGOS NV·Filed 2019·Granted Mar 9, 2021·0 cites·4 claims
- 1258US2022169653A1Pyrrolopyrimidine and pyrrolopyridine derivativesGALAPAGOS NV·Filed 2021·Application pending·0 cites
- 1357US2012095034A1Piperidine derivatives useful as orexin receptor antagonistsALVARO GIUSEPPE·Filed 2008·Application pending·0 cites
- 1457US2009022670A1Novel compoundsALVARO GIUSEPPE·Filed 2008·Application pending·0 cites
- 1556US2010267730A1Novel compoundsALVARO GIUSEPPE·Filed 2009·Application pending·0 cites
- 1653US2011257198A1Piperidine derivatives useful as orexin antagonistsALVARO GIUSEPPE·Filed 2009·Application pending·0 cites
- 1752US11136325B2Pyrrolopyrimidine and pyrrolopyridine derivativesGALAPAGOS NV·Filed 2018·Granted Oct 5, 2021·0 cites·14 claims
- 1851US2011053979A1Pyridine derivatives used to treat orexin related disordersALVARO GIUSEPPE·Filed 2009·Application pending·0 cites
- 1949US2010210667A1Imidazo [1, 2-c] pyrimidin-2-ylmethylpiperidines as orexin receptor antagonistsALVARO GIUSEPPE·Filed 2008·Application pending·0 cites
- 2049US2010144760A1Novel compoundsALVARO GIUSEPPE·Filed 2009·Application pending·0 cites
- 2146US2011288098A1Novel compoundsALVARO GIUSEPPE·Filed 2011·Application pending·0 cites
- 2242US12264156B2Compounds and pharmaceutical compositions thereof for the treatment of diseasesGALAPAGOS NV·Filed 2019·Granted Apr 1, 2025·0 cites·20 claims
- 2338US10829478B25-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritisGALAPAGOS NV·Filed 2017·Granted Nov 10, 2020·0 cites·37 claims
- 2437US10550100B25-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritisGALAPAGOS NV·Filed 2017·Granted Feb 4, 2020·0 cites·15 claims
- 2529US2012040991A13-azabicyclo [4.1.0] heptanes used as orexin antagonistsAMANTINI DAVID·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Amantini files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →